Last reviewed 2026-06-01 · How we verify

2wIPV+1sIPV

Sinovac Biotech Co., Ltd · FDA-approved active Biologic ✓ Verified Jun 2026

2wIPV+1sIPV is a Inactivated viral vaccine Biologic drug developed by Sinovac Biotech Co., Ltd. It is currently FDA-approved for Poliomyelitis prevention (poliovirus types 1, 2, and 3).

This is a combination inactivated polio vaccine regimen using two doses of whole-virus IPV followed by one dose of split-virus IPV to provide immunization against poliovirus types 1, 2, and 3.

Researchers conducted a Phase IV clinical study (NCT07457060) to evaluate the immunogenicity and safety of a sequential vaccination regimen using 2 doses of wild-type inactivated poliovirus vaccine (2wIPV) plus 1 dose of Sabin-type inactivated poliovirus vaccine (1sIPV) in individuals with poliomyelitis. This study compared the immunogenicity of this regimen to other vaccination schedules, including 1wIPV+2sIPV and 3wIPV.

At a glance

Generic name	2wIPV+1sIPV
Sponsor	Sinovac Biotech Co., Ltd
Drug class	Inactivated viral vaccine
Target	Poliovirus types 1, 2, and 3 antigens
Modality	Biologic
Therapeutic area	Immunology / Infectious Disease
Phase	FDA-approved

Mechanism of action

The 2wIPV+1sIPV schedule represents a mixed vaccination strategy combining whole-virus inactivated polio vaccine (wIPV) with split-virus inactivated polio vaccine (sIPV). The whole-virus component provides robust immunogenicity, while the split-virus component may offer improved safety profile. This heterologous prime-boost approach aims to optimize both immune response and tolerability in polio prevention.

Approved indications

Poliomyelitis prevention (poliovirus types 1, 2, and 3)

Common side effects

Local injection site reactions (pain, redness, swelling)
Fever
Irritability or fussiness

Key clinical trials

Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

2wIPV+1sIPV CI brief — competitive landscape report
2wIPV+1sIPV updates RSS · CI watch RSS
Sinovac Biotech Co., Ltd portfolio CI

Frequently asked questions about 2wIPV+1sIPV

What is 2wIPV+1sIPV?

2wIPV+1sIPV is a Inactivated viral vaccine drug developed by Sinovac Biotech Co., Ltd, indicated for Poliomyelitis prevention (poliovirus types 1, 2, and 3).

How does 2wIPV+1sIPV work?

This is a combination inactivated polio vaccine regimen using two doses of whole-virus IPV followed by one dose of split-virus IPV to provide immunization against poliovirus types 1, 2, and 3.

What is 2wIPV+1sIPV used for?

2wIPV+1sIPV is indicated for Poliomyelitis prevention (poliovirus types 1, 2, and 3).

Who makes 2wIPV+1sIPV?

2wIPV+1sIPV is developed and marketed by Sinovac Biotech Co., Ltd (see full Sinovac Biotech Co., Ltd pipeline at /company/sinovac-biotech-co-ltd).

What drug class is 2wIPV+1sIPV in?

2wIPV+1sIPV belongs to the Inactivated viral vaccine class. See all Inactivated viral vaccine drugs at /class/inactivated-viral-vaccine.

What development phase is 2wIPV+1sIPV in?

2wIPV+1sIPV is FDA-approved (marketed).

What are the side effects of 2wIPV+1sIPV?

Common side effects of 2wIPV+1sIPV include Local injection site reactions (pain, redness, swelling), Fever, Irritability or fussiness.

What does 2wIPV+1sIPV target?

2wIPV+1sIPV targets Poliovirus types 1, 2, and 3 antigens and is a Inactivated viral vaccine.

Drug class: All Inactivated viral vaccine drugs
Target: All drugs targeting Poliovirus types 1, 2, and 3 antigens
Manufacturer: Sinovac Biotech Co., Ltd — full pipeline
Therapeutic area: All drugs in Immunology / Infectious Disease
Indication: Drugs for Poliomyelitis prevention (poliovirus types 1, 2, and 3)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing